Gene therapy enters Phase III
Amsterdam Molecular Therapeutics finished enrolment in its Phase III trial in mid-June in its AAAV-based gene therapy AMT-011 (Glybera®) programme for the correction of lipoprotein lipase deficiency. The company had previously announced preliminary results from 10 patients. In nine of them, treatment was well tolerated. All patients that had fat accumulations showed improvement.